Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas

Journal of Clinical Oncology

Volumn 34, Issue 14, 2016, Pages 1669-1675

  Blakeley, Jaishri O ^a   Ye, Xiaobu ^a   Duda, Dan G ^d   Halpin, Chris F ^e   Bergner, Amanda L ^a   Muzikansky, Alona ^d   Merker, Vanessa L ^d   Gerstner, Elizabeth R ^d   Fayad, Laura M ^a   Ahlawat, Shivani ^a   Jacobs, Michael A ^a   Jain, Rakesh K ^d   Zalewski, Christopher ^b   Dombi, Eva ^c   Widemann, Brigitte C ^c   Plotkin, Scott R ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; CREATINE KINASE; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLACENTAL GROWTH FACTOR; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; ANGIOGENESIS INHIBITOR; TUMOR MARKER;

ABDOMINAL PAIN; ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC RHINITIS; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD VESSEL PERMEABILITY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HEARING IMPAIRMENT; HEART PALPITATION; HEMOGLOBINURIA; HEMOLYSIS; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MEDIASTINUM DISEASE; MENORRHAGIA; MENSTRUAL IRREGULARITY; MOUTH PAIN; MULTICENTER STUDY; NAUSEA; NEUROFIBROMATOSIS TYPE 2; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; ORAL BLEEDING; ORAL MUCOSITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEINURIA; QT PROLONGATION; RECTUM HEMORRHAGE; RESPIRATORY TRACT DISEASE; SENSORY NEUROPATHY; SIDE EFFECT; SORE THROAT; THORAX DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; VERTIGO; VOICE DISORDER; VOMITING; WEIGHT GAIN; WOUND COMPLICATION; CLINICAL TRIAL; DRUG ADMINISTRATION; HEARING LOSS; METABOLISM; MIDDLE AGED; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; PATHOPHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BIOMARKERS, TUMOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; YOUNG ADULT;

EID: 84970027716     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.3817     Document Type: Article

References (37)

1. Stangerup SE, Tos M, Thomsen J, et al: True incidence of vestibular schwannoma? Neurosurgery 67:1335-1340, 2010; discussion 1340.
2. Carlson ML, Link MJ, Wanna GB, et al: Management of sporadic vestibular schwannoma. Otolaryngol Clin North Am 48:407-422, 2015.
3. Flickinger JC, Kondziolka D, Niranjan A, et al: Results of acoustic neuroma radiosurgery: An analysis of 5 years' experience using current methods. J Neurosurg 119:1-6, 2013 (suppl).
4. Lunsford LD, Niranjan A, Flickinger JC, et al: Radiosurgery of vestibular schwannomas: Summary of experience in 829 cases. J Neurosurg 119: 195-199, 2013 (suppl).
5. Asthagiri AR, Parry DM, Butman JA, et al: Neurofibromatosis type 2. Lancet 373:1974-1986, 2009.
6. Evans DG: Neurofibromatosis type 2 (NF2): A clinical and molecular review. Orphanet J Rare Dis 4: 16, 2009.
7. Ferner RE: Neurofibromatosis 1 and neurofibromatosis 2: A twenty first century perspective. Lancet Neurol 6:340-351, 2007.
8. Plotkin SR, Merker VL, Muzikansky A, et al: Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol 35: e50-e56, 2014.
9. Blakeley JO, Evans DG, Adler J, et al: Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A 158A:24-41, 2012.
10. Fisher LM, Doherty JK, Lev MH, et al: Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: Neurofibromatosis 2 natural history consortium. Otol Neurotol 30:835-841, 2009.
11. Dewan R, Pemov A, Kim HJ, et al: Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neurooncol 17:566-573, 2015.
12. Stivaros SM, Stemmer-Rachamimov AO, Alston R, et al: Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis type 2. J Med Genet 52:557-562, 2015.
13. Sun S, Liu A: Long-term follow-up studies of GammaKnife surgery for patientswith neurofibromatosis type 2. J Neurosurg 121:143-149, 2014 (suppl).
14. Plotkin SR, Ardern-Holmes SL, Barker FG II, et al: Hearing and facial function outcomes for neurofibromatosis 2 clinical trials. Neurology 81:S25-S32, 2013 (suppl).
15. Rowe JG, Radatz MW, Walton L, et al: Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry 74: 1288-1293, 2003.
16. Samii M, Matthies C, Tatagiba M: Management of vestibular schwannomas (acoustic neuromas): Auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 40:696-705, 1997 discussion 705-706.
17. Plotkin SR, Stemmer-Rachamimov AO, Barker FG II, et al: Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358-367, 2009.
18. Dalgorf DM, Rowsell C, Bilbao JM, et al: Immunohistochemical investigation of hormone receptors and vascular endothelial growth factor concentration in vestibular schwannoma. Skull Base 18:377-384, 2008.
19. Koutsimpelas D, Stripf T, Heinrich UR, et al: Expression of vascular endothelial growth factor and basic fibroblast growth factor in sporadic vestibular schwannomas correlates to growth characteristics. Otol Neurotol 28:1094-1099, 2007.
20. Jain RK: Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26:605-622, 2014.
21. Wong HK, Lahdenranta J, Kamoun WS, et al: Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 70: 3483-3493, 2010.
22. Jain RK, di Tomaso E, Duda DG, et al: Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622, 2007.
23. Plotkin SR, Merker VL, Halpin C, et al: Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: A retrospective review of 31 patients. Otol Neurotol 33:1046-1052, 2012.
24. Slusarz KM, Merker VL, Muzikansky A, et al: Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 73:1197-1204, 2014.
25. The Consensus Development Panel: National Institutes of Health Consensus Development Conference statement on acoustic neuroma, December 11-13, 1991. Arch Neurol 51:201-207, 1994.
26. Evans DG, Huson SM, Donnai D, et al: A clinical study of type 2 neurofibromatosis. Q J Med 84:603-618, 1992.
27. Baser ME, Friedman JM, Wallace AJ, et al: Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59:1759-1765, 2002.
28. Halpin C, Rauch SD: Using audiometric thresholds and word recognition in a treatment study. Otol Neurotol 27:110-116, 2006.
29. Thornton AR, Raffin MJ: Speechdiscrimination scores modeled as a binomial variable. J Speech Hear Res 21:507-518, 1978.
30. Plotkin SR, Halpin C, Blakeley JO, et al: Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 93:61-77, 2009.
31. Harris GJ, Plotkin SR, Maccollin M, et al: Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 62:1314-1319, 2008 discussion 1319- 1320.
32. Batchelor TT, Gerstner ER, Emblem KE, et al: Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110:19059-19064, 2013.
33. Batchelor TT, Duda DG, di Tomaso E, et al: Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817-2823, 2010.
34. Gurgel RK, Jackler RK, Dobie RA, et al: A new standardized format for reporting hearing outcome in clinical trials. Otolaryngol Head Neck Surg 147: 803-807, 2012.
35. Jain RK, Duda DG, Willett CG, et al: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338, 2009.
36. Li KL, Djoukhadar I, Zhu X, et al: Vascular biomarkers derived from dynamic contrastenhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. Neuro Oncol 18:275-282, 2016.
37. Boin A, Couvelard A, Couderc C, et al: Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro-oncol 16: 1196-1209, 2014.